Publications
Detailed Information
Sulforaphane increases BDNF expression via HDAC inhibition in primary cortical neurons and 3xTg-AD mice : 일차신경세포와 치매동물 모델에서 설포라판의 HDAC 활성 저해를 통한 BDNF의 증가 및 작용기작 규명
Cited 0 time in
Web of Science
Cited 0 time in Scopus
- Authors
- Advisor
- 이기원
- Major
- 농업생명과학대학 농생명공학부
- Issue Date
- 2014-08
- Publisher
- 서울대학교 대학원
- Keywords
- sulforaphane ; brain-derived neurotrophic factor ; histone deacetylase ; Alzheimer’s disease
- Description
- 학위논문 (석사)-- 서울대학교 대학원 : 농생명공학부, 2014. 8. 이기원.
- Abstract
- Brains of patients with Alzheimers disease (AD) contain abnormally low levels of brain-derived neurotrophic factor (BDNF), a neurotrophin that regulates learning and memory and promotes the survival of injured neurons. As recent studies indicate that sulforaphane improves learning and memory in animal models, I hypothesized that sulforaphane influences synaptic activity by regulating BDNF levels. I found that sulforaphane treatment increased BDNF levels in mouse primary cortical neurons and restored frontal cortex levels of BDNF in a triple-transgenic mouse model of AD. Also, sulforaphane inhibited histone deacetylase (HDAC) and increased acetylation of histone 3 and 4, suggesting that sulforaphane regulates BDNF expression via HDAC inhibition. Furthermore, sulforaphane increased levels of several BDNF pathway components, including tyrosine kinase receptor B (TrkB), cAMP-responsive element-binding protein (CREB), Ca2+/calmodulin-dependent protein kinase II (CaMKII), extracellular signal-regulated kinase (ERK), and Akt, as well as neuronal and synaptic molecules such as microtubule-associated protein 2 (MAP2), synaptophysin, and postsynaptic density protein-95 (PSD-95). These findings suggest that sulforaphane could be used to prevent or treat AD.
- Language
- English
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.